Core Laboratories (CLB) reported fourth-quarter 2023 adjusted earnings of 19 cents per share, which missed the Zacks Consensus Estimate of 20 cents. The bottom line was also lower than the year-ago quarter’s reported figure of 20 cents. This could be attributed to poor performance in the Production Enhancement segment. However, this oilfield service provider’s operating revenues of $128 million were in line with the Zacks Consensus Estimate. The top line increased 0.3% from the year-ago quarter’s level of $127.6 million. This can be attributed to the Reservoir Description segment’s impressive performance. Core Laboratories Inc. Price, Consensus and EPS Surprise Core Laboratories Inc. Price, Consensus and EPS Surprise Core Laboratories Inc. price-consensus-eps-surprise-chart | Core Laboratories Inc. Quote Segmental Performance Reservoir Description: Revenues in this segment increased about 8.3% to $84.6 million from $78.1 million in the fourth quarter of 2022. The top line also beat our projection of $84.3 million. Operating income increased from $6.8 million in the year-ago period to $12.3 million but missed our estimate of $13.2 million. This was due to increased demand for reservoir rock and fluid analysis in international markets. Production Enhancement This segment’s revenues decreased 11.6% to $43.6 million from $49.3 million in the prior-year quarter. The figure slightly lagged our estimate of $43.7 million. Operating income of $2.2 million missed our projection of $3.5 million. The figure also deteriorated from the year-ago quarter’s level of $7.9 million due to a decrease in U.S. onshore well completion activity. Financials and Dividends As of Dec 31, 2023, Core Labs had cash and cash equivalents worth $15.1 million and long-term debt of $163.1 million. The company’s debt-to-capitalization ratio was 41.1%. CLB generated $19.4 million of operating cash in the reported quarter. Its capital expenditure totaled $2.7 million. The company’s board of directors approved a regular quarterly dividend of 1 cent per share on its common stock, payable on Mar 4, 2024, to all shareholders of record as of Feb 12, 2024. Outlook For the first quarter of 2024, revenues are anticipated to be in the range of $122-$128 million. Operating income is estimated in the band of $11.8-$14.3 million. EPS is expected between 14 cents and 18 cents. Reservoir Description revenues are expected to be in the range of $80-$84 million for the first quarter of 2024, with an operating income of $10.1-$11.9 million. Production Enhancement revenues are estimated to be in the band of $42-$44 million during the same time frame, with an operating income of $1.5-$2.2 million. Zacks Rank and Key Picks Currently, CLB carries a Zacks Rank #3 (Hold). Investors interested in the energy sector might look at some better-ranked stocks like Subsea 7 S.A. SUBCY and Oceaneering International, Inc. OII, both sporting a Zacks Rank #1 (Strong Buy), and Enbridge Inc. (ENB), carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here. Subsea 7 is valued at $4.13 billion. The company currently pays a dividend of 38 cents per share, or 2.81%, on an annual basis. SUBCY offers offshore project services for the energy industry, specializing in subsea field development, covering project management, design, engineering, procurement, fabrication, survey, installation and commissioning of seabed production facilities. Oceaneering International is worth $2.15 billion. In the past year, its shares have fallen 2.7%. The company provides engineered services and products, and robotic solutions to the offshore energy, defense, aerospace, manufacturing and entertainment industries worldwide. Enbridge is valued at $76.48 billion. The company currently pays a dividend of $2.6 per share, or 7.22%, on an annual basis. Enbridge and its subsidiaries are an energy infrastructure company with five segments — Liquids Pipelines, Gas Transmission and Midstream, Gas Distribution and Storage, Renewable Power Generation and Energy Services. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Core Laboratories Inc. (CLB):Free Stock Analysis Report Oceaneering International, Inc. (OII):Free Stock Analysis Report Enbridge Inc (ENB):Free Stock Analysis Report Subsea 7 SA (SUBCY):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Core Laboratories (CLB) Q4 Earnings Miss Estimates, Sales In Line
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...